Iterum Therapeutics plc ITRM 深 沪
等待开盘 10-03 09:30:00 美东时间
0.6697
+0.001
+0.10%
华盛通- 最 高0.6861
- 今 开0.68
- 成交量 48.05万股
- 最 低 0.66
- 昨 收 0.669
- 总市值 2678.80万
- 52周最高 3.02
- 市盈率 静 --
- 换手率 1.20%
- 52周最低 0.6108
- 委 比 95.80%
- 总股本 4000.00万
- 历史最高 195.00
- 量 比 0.73
- 振 幅 3.90%
- 历史最低 0.6108
- 每 手 1
- 风险率 0.35%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Iterum Therapeutics Provides Business Update
Iterum Therapeutics provided a business update on the launch of ORLYNVAH™ in the U.S. market, partnerships with EVERSANA, and progress in securing formulary coverage. The company also announced FDA clearance for its antimicrobial susceptibility test disc and updates on its patent portfolio in China and Mexico. Additionally, Iterum will participate in IDWeek 2025 with a presentation on urinary tract infections. The company expects its current cash...
09-19 12:00
Iterum Therapeutics Faces Shareholder Pushback on Key Proposals
Iterum Therapeutics ( ($ITRM) ) has provided an update. On September 10, 2025, ...
09-11 04:52
Iterum Therapeutics Faces Nasdaq Delisting Notice
The latest update is out from Iterum Therapeutics ( ($ITRM) ). On August 25, 20...
08-29 05:00
Iterum Therapeutics Launches New Antibiotic ORLYNVAH
Iterum Therapeutics ( ($ITRM) ) has issued an update. On August 20, 2025, Iteru...
08-20 20:45
Iterum Therapeutics Announces U.S. Commercial Launch Of ORLYNVAH Oral Tablets
Iterum Therapeutics plc (NASDAQ:ITRM), a company focused on delivering next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today
08-20 20:02
Iterum Therapeutics launches ORLYNVAH™, the first and only oral penem antibiotic in the U.S.
Iterum Therapeutics has commercially launched ORLYNVAH™, the first FDA-approved oral penem antibiotic for treating uncomplicated urinary tract infections (uUTIs) in adult women caused by certain bacteria. The drug offers a critical new option as antibiotic resistance increases, with 57% of initial infections resistant to at least one antibiotic class. ORLYNVAH™, approved in October 2024, provides a much-needed alternative for patients with limite...
08-20 12:00
CORRECTION: Iterum Therapeutics Q2 Adj. EPS $(0.13) Misses $(0.11) Estimate. Cash And Equivalents Of $13M, Runway Into 2026
Iterum Therapeutics (NASDAQ:ITRM) reported quarterly losses of $(0.13) per share which missed the analyst consensus estimate of $(0.11) by 18.18 percent. This is a 43.48 percent increase over losses of $(0.23) per share
08-05 20:49
Iterum Therapeutics Non-GAAP EPS of -$0.13
Iterum Therapeutics press release (NASDAQ:ITRM): Q2 Non-GAAP EPS of -$0.13. Cash and cash equivalents were $13.0 million as of June 30, 2025. Based on Iterum’s current operating plan, Iterum expects t...
08-05 19:16
Earnings Scheduled For August 5, 2025
Companies Reporting Before The Bell • Silicon Laboratories (NASDAQ:SLAB) is exp...
08-05 16:32
Insights Ahead: Iterum Therapeutics's Quarterly Earnings
Iterum Therapeutics (NASDAQ:ITRM) is preparing to release its quarterly earning...
08-05 05:03
